title: The 4-acetylantroquinonol B isolated from mycelium of Antrodia cinnamomea inhibits proliferation of hepatoma cells.
abstract: BACKGROUND
  Antrodia cinnamomea is known for its antihepatoma activity, yet the identity of its active compound was unclear. In this study, a 5-ton fermenter was used to prepare sufficient mycelium of A. cinnamomea for active compound isolation and identification.
  
  
  RESULTS
  Using antiproliferative activity toward HepG2 cells as guidance in the isolation process, 4-acetylantroquinonol B was purified and identified to be the major bioactive compound of A. cinnamomea cultivated by submerged fermentation. The median effective doses (EC(50)) of 4-acetylantroquinonol B for HepG2 cells were 0.10 +/- 0.00 and 0.08 +/- 0.00 microg mL(-1) for 72 and 96 h treatments, respectively. The selective indices of 4-acetylantroquinonol B were 100 and 125 for 72 and 96 h treatments, respectively, indicating that this compound had high selective activity for hepatoma cells.
  
  
  CONCLUSIONS
  4-Acetylantroquinonol B is the major antihepatoma constituent of Antrodia cinnamomea mycelium produced by submerged fermentation.
authors.affiliation: Institute of Food Science and Technology, National Taiwan University, No. 1 Sec. 4 Roosevelt Road, Taipei, Taiwan, ROC.
authors.forename: Yu-Wei
authors.initials: YW
authors.lastname: Lin
authors.forename: Jih-Hung
authors.initials: JH
authors.lastname: Pan
authors.forename: Rui Hai
authors.initials: RH
authors.lastname: Liu
authors.forename: Yueh-Hsiung
authors.initials: YH
authors.lastname: Kuo
authors.forename: Lee-Yen
authors.initials: LY
authors.lastname: Sheen
authors.forename: Been-Huang
authors.initials: BH
authors.lastname: Chiang
mesh_terms: D015107:4-Butyrolactone / Q000031:analogs & derivatives* / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D055491:Antrodia / Q000737:chemistry*; D001688:Biological Products / Q000494:pharmacology* / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D049109:Cell Proliferation / Q000187:drug effects*; D003512:Cyclohexanones / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D005285:Fermentation; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D025282:Mycelium
chemical_list: D000970:Antineoplastic Agents; D001688:Biological Products; D003512:Cyclohexanones; C555021:4-acetylantroquinonol B; D015107:4-Butyrolactone